Christopher Mutz Sells 5,323 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) insider Christopher Mutz sold 5,323 shares of the business’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $78.02, for a total value of $415,300.46. Following the transaction, the insider owned 84,840 shares of the company’s stock, valued at $6,619,216.80. The trade was a 5.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

ANI Pharmaceuticals Trading Down 3.4%

Shares of NASDAQ:ANIP traded down $2.67 during mid-day trading on Monday, reaching $75.10. The stock had a trading volume of 336,650 shares, compared to its average volume of 466,618. The firm has a 50 day simple moving average of $80.82 and a two-hundred day simple moving average of $86.59. ANI Pharmaceuticals, Inc. has a twelve month low of $54.10 and a twelve month high of $99.50. The firm has a market cap of $1.69 billion, a PE ratio of 46.07 and a beta of 0.50. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several hedge funds have recently made changes to their positions in ANIP. Vanguard Group Inc. lifted its position in shares of ANI Pharmaceuticals by 2.2% in the fourth quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after purchasing an additional 27,598 shares in the last quarter. Global Alpha Capital Management Ltd. increased its position in shares of ANI Pharmaceuticals by 17.2% during the 2nd quarter. Global Alpha Capital Management Ltd. now owns 862,090 shares of the specialty pharmaceutical company’s stock worth $56,251,000 after purchasing an additional 126,500 shares during the last quarter. State Street Corp grew its position in shares of ANI Pharmaceuticals by 2.2% in the 4th quarter. State Street Corp now owns 727,204 shares of the specialty pharmaceutical company’s stock valued at $57,405,000 after acquiring an additional 15,496 shares during the period. UBS Group AG grew its holdings in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock worth $54,032,000 after purchasing an additional 185,172 shares during the period. Finally, Tang Capital Management LLC raised its stake in ANI Pharmaceuticals by 51.6% in the fourth quarter. Tang Capital Management LLC now owns 481,437 shares of the specialty pharmaceutical company’s stock valued at $38,005,000 after buying an additional 163,937 shares during the period. 76.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on ANIP. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Barclays started coverage on ANI Pharmaceuticals in a report on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target for the company. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Finally, Guggenheim increased their target price on ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $103.43.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.